{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T04:40:03Z","timestamp":1789620003758,"version":"build-2803163510"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2018,4,25]],"date-time":"2018-04-25T00:00:00Z","timestamp":1524614400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1007\/s40273-018-0661-2","type":"journal-article","created":{"date-parts":[[2018,4,25]],"date-time":"2018-04-25T01:49:12Z","timestamp":1524620952000},"page":"1299-1308","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Etelcalcetide for Treating Secondary Hyperparathyroidism: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal"],"prefix":"10.1007","volume":"36","author":[{"given":"Micah","family":"Rose","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1682-4330","authenticated-orcid":false,"given":"Jonathan","family":"Shepherd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Pickett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Lord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,4,25]]},"reference":[{"key":"661_CR1","unstructured":"National Institute for Health and Care Excellence. Etelcalcetide for treating secondary hyperparathyroidism: technology appraisal guidance [TA448]. 2017. Available at: https:\/\/www.nice.org.uk\/guidance\/ta448 . Accessed 27 Mar 2018."},{"key":"661_CR2","doi-asserted-by":"publisher","first-page":"913","DOI":"10.2215\/CJN.06040710","volume":"6","author":"J Cunningham","year":"2011","unstructured":"Cunningham J, Locatelli F, Rodriguez M. Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol. 2011;6:913.","journal-title":"Clin J Am Soc Nephrol"},{"key":"661_CR3","unstructured":"Arbor Research Collaborative for Health. 2012 Annual Report of the Dialysis Outcomes and Practice Patterns Study: Hemodialysis Data 1997\u20132011. 2012. Available at: http:\/\/www.dopps.org\/AnnualReport\/ ."},{"key":"661_CR4","doi-asserted-by":"publisher","first-page":"184321","DOI":"10.1155\/2015\/184321","volume":"2015","author":"E Hedgeman","year":"2015","unstructured":"Hedgeman E, Lipworth L, Lowe K, Saran R, Do T, Fryzek J. International burden of chronic kidney disease and secondary hyperparathyroidism: a systematic review of the literature and available data. Int J Nephrol. 2015;2015:184321.","journal-title":"Int J Nephrol."},{"issue":"Suppl 1","key":"661_CR5","first-page":"1","volume":"132","author":"F Caskey","year":"2016","unstructured":"Caskey F, Cullen R. UK Renal Registry 18th Annual Report 2015. Nephron. 2016;132(Suppl 1):1\u20138.","journal-title":"Nephron"},{"key":"661_CR6","unstructured":"National Institute for Health and Care Excellence. Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy. Technology appraisal guidance [TA117]. 2007. Available at: https:\/\/www.nice.org.uk\/guidance\/ta117 . Accessed 27 Mar 2018."},{"key":"661_CR7","unstructured":"Kidney Disease: Improving Global Outcomes. KDIGO Clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int. 2009;76(Suppl 113):S1\u2013130."},{"issue":"2","key":"661_CR8","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1001\/jama.2016.19456","volume":"317","author":"GA Block","year":"2017","unstructured":"Block GA, Bushinsky DA, Cunningham J, Drueke TB, Ketteler M, Kewalramani R, et al. Effect of etelcalcetide vs placebo on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: two randomized clinical trials. JAMA. 2017;317(2):146\u201355.","journal-title":"JAMA"},{"issue":"2","key":"661_CR9","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1001\/jama.2016.19468","volume":"317","author":"GA Block","year":"2017","unstructured":"Block GA, Bushinsky DA, Cheng S, Cunningham J, Dehmel B, Drueke TB, et al. Effect of etelcalcetide vs cinacalcet on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: a randomized clinical trial. JAMA. 2017;317(2):156\u201364.","journal-title":"JAMA"},{"key":"661_CR10","unstructured":"Bushinsky D, Block G, Cheng S, Deng H, Ure\u00f1a-Torres P, Vervloet M, et al. One year efficacy and safety of intravenous etelcalcetide (amg 416) in patients on hemodialysis with secondary hyperparathyroidism (Study 20120231). In: 53rd ERA-EDTA Congress: 21\u201324 May 2016, Vienna."},{"key":"661_CR11","unstructured":"Amgen data on file. Study 20130213 Interim analysis summary 2016."},{"key":"661_CR12","unstructured":"Liss K, Block G, Chertow GM, Dehmel B, Sun Y, Spiegel DM. Initiation of AMG 416 (etelcalcetide) after discontinuation of cinacalcet; TH-PO871. In: American Society of Nephrology; 3\u20138 Nov 2015: San Diego."},{"key":"661_CR13","doi-asserted-by":"crossref","unstructured":"Garside R, Pitt M, Anderson R, Mealing S, Roome C, Snaith A, et al. The effectiveness and cost-effectiveness of cinacalcet for secondary hyperparathyroidism in end-stage renal disease patients on dialysis: a systematic review and economic evaluation. Health Technol Assess. 2007;11(18):iii, xi\u2013xiii.","DOI":"10.3310\/hta11180"},{"issue":"8","key":"661_CR14","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/j.jval.2015.08.007","volume":"18","author":"V Belozeroff","year":"2015","unstructured":"Belozeroff V, Chertow GM, Graham CN, Dehmel B, Parfrey PS, Briggs AH. Economic evaluation of cinacalcet in the united states: the EVOLVE trial. Value Health. 2015;18(8):1079\u201387.","journal-title":"Value Health."},{"issue":"26","key":"661_CR15","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1056\/NEJMoa1205624","volume":"367","author":"GM Chertow","year":"2012","unstructured":"Chertow GM, Block GA, Correa-Rotter R, Dr\u00fceke TB, Floege J, Goodman WG, et al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med. 2012;367(26):2482\u201394.","journal-title":"N Engl J Med."},{"issue":"11","key":"661_CR16","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.2165\/11538600-000000000-00000","volume":"28","author":"M Eandi","year":"2010","unstructured":"Eandi M, Pradelli L, Iannazzo S, Chiroli S, Pontoriero G. Economic evaluation of cinacalcet in the treatment of secondary hyperparathyroidism in Italy. Pharmacoeconomics. 2010;28(11):1041\u201354.","journal-title":"Pharmacoeconomics."},{"issue":"8","key":"661_CR17","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1177\/0272989X16638312","volume":"36","author":"AH Briggs","year":"2016","unstructured":"Briggs AH, Parfrey PS, Khan N, Tseng S, Dehmel B, Kubo Y, et al. Analyzing health-related quality of life in the EVOLVE trial: the joint impact of treatment and clinical events. Med Decis Mak. 2016;36(8):965\u201372.","journal-title":"Med Decis Mak"},{"issue":"3","key":"661_CR18","doi-asserted-by":"publisher","first-page":"198","DOI":"10.3111\/13696998.2013.869227","volume":"17","author":"RD Pockett","year":"2014","unstructured":"Pockett RD, Cevro E, Chamberlain G, Scott-Coombes D, Baboolal K. Assessment of resource use and costs associated with parathyroidectomy for secondary hyperparathyroidism in end stage renal disease in the UK. J Med Econ. 2014;17(3):198\u2013206.","journal-title":"J Med Econ."},{"key":"661_CR19","doi-asserted-by":"crossref","unstructured":"Latimer NR, Abrams KR. NICE DSU Technical Support Document 16: Adjusting survival time estimates in the presence of treatment switching. 2014. Available at: http:\/\/nicedsu.org.uk\/technical-support-documents\/treatment-switching-tsd\/ . Accessed 27 Mar 2018.","DOI":"10.1016\/j.jval.2013.08.013"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40273-018-0661-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-018-0661-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-018-0661-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,20]],"date-time":"2022-08-20T22:34:27Z","timestamp":1661034867000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40273-018-0661-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,25]]},"references-count":19,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["661"],"URL":"https:\/\/doi.org\/10.1007\/s40273-018-0661-2","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,25]]},"assertion":[{"value":"25 April 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This project was funded by the National Institute for Health Research (NIHR) HTA Program (project number 16\/10\/01 STA) [see the NIHR Journals Library website for further information\u2014]. The views and opinions expressed herein are the authors and do not necessarily reflect those of the HTA Programme, NICE, NIHR, NHS, or the Department of Health. Any errors are the responsibility of the authors. This summary of the ERG report was compiled after NICE issued the Final Appraisal Determination.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Micah Rose, Jonathan Shepherd, Petra Harris, Karen Pickett and Joanne Lord declare no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}